Drugs / VRC-ADJDNA004-IL2-VP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00069030 | Dec 2003 → Dec 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-ADJDNA004-IL2-VP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00069030 ↗ |
| Modality | Other / unclassified | “The adjuvant is a DNA plasmid encoding interleukin 2 (IL-2) fused to the Fc portion of IgG for enhanced stability.” NCT00069030 ↗ |
| Route | Other | “All injections will be administered by needle-free injection in the upper arm.” NCT00069030 ↗ |